Show simple item record

dc.contributor.authorSoliman, Rasha Hassan
dc.contributor.authorGarcia-Aranda, Patricia 
dc.contributor.authorElzagawy, Sherine Mohamed
dc.contributor.authorHussein, Boshra El-Sayed
dc.contributor.authorMayah, Wael Wahid
dc.contributor.authorMartin-Ramirez, Alexandra 
dc.contributor.authorTa Tang, Thuy-Huong 
dc.contributor.authorRubio Muñoz, Jose Miguel 
dc.date.accessioned2019-05-20T09:38:35Z
dc.date.available2019-05-20T09:38:35Z
dc.date.issued2018-08-07
dc.identifier.citationMalar J. 2018 Aug 7;17(1):286.es_ES
dc.identifier.issn1475-2875es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7598
dc.descriptionFollowing publication of the original article [1], it was flagged by one of the authors that the name of the P. falci-parum gene marker of artemisinin resistance ‘pfkelch13’ was (incorrectly) written as “pfketch13”, which was repeated seven times in different parts of the published p ap e r.As such, please note that “pfketch13” in the article [1] should in fact be pfkelch13.Se incluye corrección en pdf.es_ES
dc.description.abstractBACKGROUND: The Kingdom of Saudi Arabia is seeking malaria eradication. Malaria transmission has been very low over the last few years. Discovered cases of Plasmodium falciparum infection are assigned a treatment protocol of artemisinin-based combination therapy, which consists of artesunate in addition to sulfadoxine-pyrimethamine rather than the traditional chloroquine, which has high resistance rates worldwide. This study aims to investigate the presence of different gene mutations concerning anti-malarial drug resistance (pfdhfr, pfdhps, pfmdr1, pfcrt, pfcytb, pfketch13) to identify whether drug-resistant alleles are present in this area of the Kingdom and whether the country's treatment protocol is still suitable for Plasmodium bearing a resistance mutation. METHODS: Blood samples were collected from patients suffering from symptoms suggesting malaria coming to King Faisal Hospital, Taif, from February to August 2016. Diagnosis was performed by Giemsa-stained thin and thick blood films, rapid diagnostic test and PCR. Positive P. falciparum samples were further subjected to series of PCR amplification reactions targeting genes related with drug resistance (pfdhfr, pfdhps, pfmdr1, pfcrt, pfcytb, pfketch13). RESULTS: Twenty-six cases were positives, 13 infected with P. falciparum, of those, 4 cases were autochthonous, and 13 with Plasmodium vivax. The results of the gene mutation detection confirmed that there was no mutation related to resistance to artemisinin or atovaquone, on the other hand chloroquine resistance alleles were detected in 31% of samples. Moreover, point mutations in the pfdhfr and pfdhps genes, related resistance to antifolate drugs, were detected in all characterized samples. CONCLUSIONS: Haplotypes of P. falciparum in the western region of the Kingdom of Saudi Arabia exhibit high resistance against antifolate drugs. These results should be extensively discussed when planning to modify anti-malarial drug protocols in the future.es_ES
dc.description.sponsorshipThis work was partially supported by the Spanish Strategic Health Action (AESI-ISCIII) Grant Number PI14CIII/00014.es_ES
dc.language.isoenges_ES
dc.publisherBMCes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAntifolate drugses_ES
dc.subjectDrug resistancees_ES
dc.subjectIndigenous caseses_ES
dc.subjectPlasmodium falciparumes_ES
dc.subjectSaudi Arabiaes_ES
dc.subject.meshAdult es_ES
dc.subject.meshCommunicable Diseases, Imported es_ES
dc.subject.meshDrug Resistance es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMalaria, Falciparum es_ES
dc.subject.meshMale es_ES
dc.subject.meshMutation es_ES
dc.subject.meshPlasmodium falciparum es_ES
dc.subject.meshProtozoan Proteins es_ES
dc.subject.meshSaudi Arabia es_ES
dc.subject.meshYoung Adult es_ES
dc.titleImported and autochthonous malaria in West Saudi Arabia: results from a reference hospitales_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID30086757es_ES
dc.format.volume17es_ES
dc.format.number1es_ES
dc.format.page286es_ES
dc.identifier.doi10.1186/s12936-018-2438-7es_ES
dc.contributor.funderInstituto de Salud Carlos III - ISCIIIes_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1475-2875es_ES
dc.relation.publisherversionhttps://doi.org/10.1186/s12936-018-2438-7es_ES
dc.identifier.journalMalaria journales_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional